| Phase 3 Study of Intravitreal 4D-150 in Adults With Diabetic Macular Edema (DME) (4D-150-C005) | eye disorder | Recruiting | Phase 3 | 2026-10-09 | | NCT07867080 |
|---|
| A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 3 | 2026-10-06 | | NCT06510816 |
|---|
| CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-10-02 | | NCT07449923 |
|---|
| A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema | eye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder | Recruiting | Phase 2 | 2026-10-01 | | NCT06962839 |
|---|
| A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-30 | | NCT06635148 |
|---|
| Extension Study for the Port Delivery System With Ranibizumab (Portal) | Neovascular Age-Related Macular Degeneration | Recruiting | Phase 3 | 2026-09-28 | | NCT03683251 |
|---|
| A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 | 2026-09-23 | | NCT06557460 |
|---|
| ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) | eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 3 | 2026-09-17 | | NCT06373731 |
|---|
| Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 | 2026-09-10 | | NCT06659445 |
|---|
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | wet macular degeneration | Active, not recruiting | Phase 3 | 2026-09-03 | | NCT06668064 |
|---|
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME) | diabetic macular edema | Active, not recruiting | Phase 1 | 2026-09-02 | | NCT06847854 |
|---|
| 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Recruiting | Phase 1 / Phase 2 | 2026-08-21 | | NCT05197270 |
|---|
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Enrolling by invitation | Phase 2 | 2026-08-05 | | NCT05296447 |
|---|
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD | Neovascular Age-Related Macular Degeneration (nAMD) | Enrolling by invitation | Phase 2 | 2026-08-05 | | NCT05210803 |
|---|
| 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-06-01 | | NCT06864988 |
|---|
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | Wet Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2026-04-29 | | NCT06556368 |
|---|
| Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) | Neovascular (Wet) AMD | Active, not recruiting | Phase 1 / Phase 2 | 2026-02-12 | | NCT06550011 |
|---|
| Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | Neovascular Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2025-06-17 | | NCT06495918 |
|---|
| Retina BioBank: Retina Biomarkers for a Deeper Understanding of Vitreoretinal and Systemic Diseases | eye disorder, retinal disorder, retinal vascular disorder | Enrolling by invitation | Not stated | 2025-01-28 | | NCT06796673 |
|---|